45 results about "Protein dna" patented technology

The present invention provides methods and compositions for interaction trap assays for detecting protein-protein, protein-DNA, or protein-RNA interactions. The methods and compositions of the invention may also be used to identify agents which may agonize or antagonize a protein-protein, protein-DNA, or protein-RNA interaction. In certain embodiments, the interaction trap system of the invention is useful for screening libraries with greater than 10⁷ members. In other embodiments, the interaction trap system of the invention is used in conjunction with flow cytometry. The invention further provides a means for simultaneously screening a target protein or nucleic acid sequence for the ability to interact with two or more test proteins or nucleic acids.

The invention belongs to the field of preparing a nanomaterial, and particularly relates to a magnetic fluorescent double-function nanoion probe and a preparation method thereof. The composite microparticles have the fluorescent performance of quantum dots and the magnetism performance of magnetic nanoparticles, and can be used as target positioning in biological body and biological fluorescent imaging aspects. The invention provides a preparation method of the magnetic fluorescent double-function nanomaterial, and the magnetic fluorescent double-function nanomaterial is obtained by taking chitosan-modified magnetic nanoparticles as a core and connecting water-soluble quantum dots through adopting an ionic crosslinked method, the fluorescent quantum dots are distributed on the surfaces of the magnetic nanoparticles with the particle size of 10-200nm, and the particle size of the quantum dots is 1.5-10nm. The preparation method is mild in reaction conditions, the operation method is simple, the prepared composite nanoparticles have good luminescence performance and magnetic performance, and have wide application prospects in the fields of biomarking, fluorescent immunoassay, bioseparation, protein DNA enrichment and separation, the preparation of drug carrying system, and target imaging and the like.

The invention provides compositions and methods of identifying and testing TGF- beta pathway agonists and antagonists, and in particular compositions comprising Mothers against DPP (MAD) proteins and related Smad polypeptides which exhibit sequence-specific DNA-binding activity. The invention also provides a novel DNA sequence (SEQ ID NO:19); (SEQ ID NO:20); (SEQ ID NO:21) that is bound with high affinity by Drosophila MAD protein. This protein is useful for identifying compounds that will enhance or interfere with MAD protein-DNA binding.

A library of multimeric DNA binding polypeptides is provided. Preferred such polypeptides are zinc finger protein DNA binding domains. Libraries of nucleotides encoding such polypeptides, expression vectors containing such nucleotides, cells containing any of the libraries and uses of the libraries are also provided.

The invention discloses a side unit used for building TALE (transcription activator-like effector) repeated sequences. The side unit is a repeated unit DNA (deoxyribonucleic acid) segment containing isocaudarner or different flat terminase identification sites at two ends, and the preated unit DNA segment codes repeated units of RVD (repeated variable di-residue) containing NI, NG, HD, NK or NN or variants of the repeated units, wherein in the 5'end isocaudarner or flat terminase identification sites, the 3' end of the identification sites at least has one nucleotide participating in the amino acid coding the N end of the side unit; and in the 3' end isocaudarner or flat terminase identification sites, the 5' end of the identification sites at least has one nucleotide participating in the amino acid coding the C end of the side unit. The side unit has the advantages that the TALE repeated sequences containing any repeated unit number and any ranging sequences, plasmid vectors containing TALE repeated sequences, coding TALE protein DNA combined structural domains and various derived fusion protein plasmid vectors can be conveniently built.

The invention discloses a protein-DNA binding residue prediction method based on sampling and integrated learning. The method comprises the steps of (1) feature extraction and training sample set construction, (2) sampling and model training, (3) model integration, and (4) online prediction. The method is used for solving the shortcomings of low prediction precision caused by the problems of few feature types and class imbalance in protein-DNA binding residue prediction problems and has the advantages of high prediction precision and high generalization ability.

Compositions and methods are provided for detecting and measuring DNA-binding proteins. The compositions and methods permit the simultaneous or near-simultaneous detection of multiple DNA-binding proteins in a multiplex or array format, and can be used to generate profiles of DNA binding activity by proteins, specifically, transcription factors. Multiple protein-DNA binding events in a single sample may be detected and quantitated in a high-throughput format.

The present invention provides a multi-core-learning and Boosting algorithm based protein-DNA binding site prediction method. The method comprises the following steps: feature extraction, extracting an evolutionary information feature vector and a solvent accessibility feature vector of each amino acid residue; feature fusion, using a linear kernel based multi-core-learning algorithm to carry out evaluation on weight information of the two feature vectors, and according to the weight, carrying out weighted serial combination to obtain a final sample feature vector; using a random downsampling technology to carry out multiple downsampling on non-binding site samples, combining a non-binding site sample subset obtained by downsampling and a binding site sample set to train an SVM, and obtaining a plurality of SVM prediction models; and using a Boosting lifting algorithm to carry out integration on the SVM models, and forming a final prediction model. The method disclosed by the present invention improves model interpretability, effectively reduces the size of the training set, and improves the prediction precision of the model.

DNA isolates coding for tissue factor protein and methods of obtaining such DNA and producing tissue factor protein using recombinant expression systems for use in therapeutic composition for the treatment of coagulation disorders.

The present invention discloses a fusional protein of a serum albumin and an interferon, the coding of the fusional protein DNA sequence, as well as bacteria, barm, animal cell and plant cell of the DNA sequence. The fusional protein provided by the present invention includes a first district with at least 85 percents congeneric sequence of the artificial serum albumin and a second district with at least 85 percents congeneric sequence of the artificial interferon. Without changing the property of the fusional protein, the fusional protein can implement the replacement, deficit or addition of exceptional amide acid residue. A connecting peptide is arranged between the first district and the second district of the fusional protein provided by the present invention; the general formula of the connecting peptide is [GlyGly GlyGlySer]n and n is an integer from 1 to 10. The fusional protein provided by the present invention with the property of artificial interferon and prolonged half-value period will be widely applied in the medicine field.

The invention relates to firefly luciferase and an encoding gene and an obtaining method thereof. The defect that the original firefly luciferase in North America is poor in heat stability and cannot be used at a high temperature is overcome; and the original firefly luciferase in North America is mutated, so that mutative enzyme of which the heat stability is obviously improved is obtained; and the application value is improved. An amino acid sequence is SEQ ID NO.1; and a protein deoxyribonucleic acid (DNA) sequence in encoding is SEQ ID NO.2. An encoding gene and a preparation method of firefly luciferase mutant in North America are provided. By the method, a recombinant expression vector containing a wild firefly luciferase gene is built; and the protein is purified by using an affinity chromatography method. The method is simple and feasible, simple to operate, and low in cost.

The invention discloses an efficient transgenosis method with mediation of a transcription activator-like effector (TALE) protein. The method comprises the steps that a helper plasmid containing a transcription activator-like effector protein DNA (Deoxyribonucleic Acid) sequence and piggyBac transposon (PBase) DNA sequence is constructed by adopting a molecular biological technique, and transcribed to mRNA (Messenger Ribonucleic Acid) in vitro; mRNA of the helper plasmid and DNA of a piggyBac transposon plasmid containing an exogenous gene are imported to a fertilized egg of an animal by adopting a microinjection method; a transgenic animal of which the exogenous gene can be stably inherited and expresses is obtained; and a transgenosis positive individual is screened out according to a marker gene or the expression characteristic of the gene. With the adoption of the method, a piggyBac transposon can be efficiently inserted into a genome of a host organism by the action of a TALE-PBase fusion protein; the transgenosis efficiency mediated by the piggyBac transposon can be improved remarkably; and helps are offered to researches such as transgenic animal acquirement and insertion mutagenesis.

The invention provides a method for separating DNA (deoxyribonucleic acid) binding protein and accurately positioning DNA binding site, which comprises the following steps: DNA binding protein separation: carrying out PCR (polymerase chain reaction) amplification on a DNA segment to be researched by using biotin-labeled primers, sequentially adding nucleoprotein or cytoplast protein and avidin-coated magnetic beads, co-incubating, washing off nonspecific binding protein, and adding SDS (sodium dodecylsulfate) to denature and release the protein; and protein DNA binding site positioning: by using the DNA segment to be researched as a template, carrying out PCR reaction by using different primers to obtain overlapping DNA segments, and positioning the DNA binding site of the isolated protein according to the affinity difference of the overlapping DNA segments for the isolated protein.

The invention discloses a preparation method of human galectin-9 deletant for enhancement of immune response, which adopts an expression vector with a protein DNA sequence and a host cell transformed with the expression vector. The invention also provides application of the human galectin-9 deletant in improvement of cellular immunity. The protein has the function of promoting the activation of DC cells and macrophages, the demonstration of the function of the protein is the enhancement of the cellular immune response, and the immunity is suppressed in case of lack of the human galectin-9 holoprotein.

The invention relates to an analysis method for the geometrical structure characteristics of DNA binding protein interface, belonging to the technical field of biological computing. The present invention first derives proteins-DNA binding site information from proteins-DNA complex dataset; and then based on the protein-DNA Binding Site Information, residue Morphological Index and Spatial Environment of proteins-DNA Binding Sites are determined; finally, the morphological index and spatial environment of the identified protein-DNA binding sites are used as feature vectors to classify the obtained feature vectors by using classification model. As the binding specificity of double-stranded DNA binding protein (DSBs) and single-stranded DNA binding proteins (SSBs) is analyzed from the angles of the morphological structure of the residues and the characteristics of the space environment, the invention is conducive to the in-depth understanding of the proteins, and the binding specificity ofthe double-stranded DNA binding proteins and the single-stranded DNA binding proteins is analyzed. Based on the DNA binding mechanism, the present invention can also be applied to proteins-RNA, protein-Protein and other fields.

The invention relates to a method for determining a transcriptional control complex, and belongs to the field of molecular biology. The method for determining the transcriptional control complex includes the following steps: preparation of a bait DNA sequence, preparation of a DNA sequence for encoding a bar code protein, construction of a bar code protein library, screening of the transcriptional control complex, and in situ adjacent connection capture of the transcriptional control complex, and the identification of the transcriptional control complex. The invention combines cDNA display technology and the adjacent connection technology to establish a novel method for determining the transcriptional control complex; the determination of transcriptional control complex involves simultaneous determination of a variety of interaction effects of protein-protein and protein-DNA; and the method can realize simultaneous determination of a variety of interaction effects of protein-protein and protein-DNA in a same experimental system, and effectively solve the incompatibility of the determination methods for the protein-protein interaction and protein-DNA interaction in the same experimental system in the prior art.

The present invention relates to a bioactive carbon nanotube composite functionalized with a β-sheet polypeptide block copolymer by combination self-assembly, which shows excellent water dispersion, and has biological activity so as to be used as stimulus-responsive and adaptable biomaterials or in the manufacture of CNT-based electronic biosensor devices. In addition, the bioactive carbon nanotube composite can be used as a composition for delivery of a biological active material into cells. Further, the application of the interaction between a β-sheet peptide and a carbon-based hydrophobic material is expected to be useful for designing and developing an inhibitor for diseases caused by the abnormal folding of a protein and by biomacromolecular interactions (protein-protein, protein-DNA, and protein-RNA interactions etc).

The invention relates to a nano particle composition and anti-tumor application thereof. The nano particle composition is a nano particle formed by assembling a polymer carrier and plasmid for expressing a therapeutic gene; the polymer carrier is a cyclodextrin-polyethyleneimine-polyethylene glycol-folic acid quaternary assembly-type polycation carrier, and the plasmid for expressing the therapeutic gene is eukaryotic expression plasmid containing an HGFK1 protein DNA sequence for coding a hepatocyte growth factor. Compared with the prior art, the nano particle has the advantages of being efficient and tumor targeted; the nano particle can be automatically assembled in an aqueous solution through electrostatic interaction, and the particle size of the nano particle and the stability in a salt solution has an important effect on the function of the nano particle; it is verified that the nano particle composition can prevent transfer or relapse of a cancer and alleviate or relieve or control or improve or cure a primary cancer or a metastatic cancer or other related symptoms and can also prolong the life or survival time of a cancer patient and reduce the mortality.

A chimeric transactivator comprises a transcription activation domain, a repressor protein DNA binding domain and the bacterial DNA gyrase B subunit. A target gene is operatively linked to operator DNA sequences recognized by the repressor binding domain. The addition of the antibiotic coumermycin results in a coumermycin-switched dimerization of the transactivator, which then binds to operator DNA sequences and activates transcription of the target gene. The addition of novobiocin switches off expression of the target gene by abolishing coumermycin-induced dimerization of the transactivator.

DNA isolates coding for tissue factor protein and methods of obtaining such DNA and producing tissue factor protein using recombinant expression systems for use in therapeutic composition for the treatment of coagulation disorders.

A mycobacterium tuberculosis 38KD protein DNA extraction and recombinant vector construction expressing method comprises the steps of amplification and identification of 38KD protein cDNA, construction of a prokaryotic expression vector MTB38KD, expression and identification of a MTB38KD protein and purification of an 8KD protein.